Portfolio company
Curegenix
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops small-molecule chemical drugs for the treatment of tumours and organ fibrosis for patients with stem cell related diseases.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Curzion Pharmaceuticals
This biopharmaceutical company develops oral small molecule therapies to treat patients with rare fibrotic conditions like diffuse cutaneous systemic sclerosis.
Curileum
The company develops novel therapies and small molecule drugs to restore gastrointestinal tissue health for patients with bowel cancer and inflammatory bowel disease.
CureAge
This company develops curative gene therapies for patients with neurofibromatosis type 1 and other peripheral nerve diseases using lipid nanoparticle technology.
Origo Biopharma
This clinical-stage biotechnology company develops small molecule therapies targeting the transforming growth factor beta pathway to treat fibrosis and cancer in healthcare patients.
CuraSen Therapeutics
This biopharmaceutical company develops small molecule drugs to treat patients with neurodegenerative disorders, such as Parkinson's and Alzheimer's disease.
Chromacure
This company develops small molecule therapeutics for oncology patients to address unmet clinical needs in cancer treatment.
Alevin Therapeutics
This biotechnology company develops small molecule integrin inhibitors to treat patients with life-threatening fibrotic diseases, including lung, liver and kidney conditions.
Redx Pharma
This clinical-stage biotechnology company develops small molecule medicines for fibrotic diseases and oncology for pharmaceutical partners and patients with unmet medical needs.